Combined Synopsis Solicitation-COMPETITIVE_75N95023Q00181.pdf

COMBINED SYNOPSIS / SOLICITATION

COMPETITIVE

Title: 3D Liver Microtissues Composed of Human Primary Hepatocytes and a Mixture of Human Primary Hepatocyte, Liver Endothelial Cells and Kupffer Cells

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95023Q00181 and the solicitation is issued as an request for quotation (RFQ) This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplif ied Acquisition Procedures; FAR Subpart 13.5—Simplif ied Procedures for Certain Commercial Items;

and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplif ied Acquisition Procedures; FAR Subpart 13.5— Simplif ied Procedures for Certain Commercial Items;

and FAR Part 12—Acquisition of Commercial Items, and is expected to exceed the simplif ied acquisition threshold.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular Circular (FAC) Number 2022-06, with effective date May 26, 2022.

(iv) The associated NAICS code 325414, Biological Product (except Diagnostic) Manufacturing, and the small business size standard of 1,250 employees. The requirement is full and open with no set-aside restrictions.

(v) This requirement is for the following commercial item, 3D Liver Microtissues Composed of Human Primary Hepatocytes and a Mixture of Human Primary Hepatocyte, Liver Endothelial Cells and Kupffer. The National Center for Advancing Translational Sciences (NCATS) requires 3D live microtissues composed of human primary hepatocytes and a mixture of human primary hepatocyte, liver endothelial cells and Kupffer cells. These 3D liver microtissues will be used to study viral infectivity, effects of viral infectivity on liver function biomarkers, and effect of anti-viral compounds on viral infection. The liver microtissues of different cell type composition will allow use to assess the role of the different cell types on the readouts above. If sucessful, this assay platform of 3D liver microtussues might be integrated in a panel of tissues to study panels of viruses and anti-infective drugs

(vi) Generic name of the requested commercial item is identified as life and functional pre-assembled 3D liver tissues containing human primary hepatocytes (single cell type), containing human primary hepatocyte, liver endothelial cells and kupffer cells, in a multiwell plate format (96- or 384-well plate), shipped life and ready to use.

Purchase Description: 3D InSight™ Human Liver Microtissues (multi-donor hepatocytes), one tissue in each well of a 384-well plate, 3D InSight™ Human Liver MT (multi-donor hepatocytes, co-culture with Kupffer cells and LECs), one tissue in each well of a 96-well plate, and media necessary to culture the liver tissues

Salient Characteristics: Life and functional, pre-assembled 3D liver tissues containing human primary hepatocytes (single cell type) and containing human primary hepatocyte, liver endothelial cells and kupffer cells, in an HTS compatible multiwell plate format (96- or 384-well plate), shipped life and ready to use for bioloigical and drug testing upon receipt. Quantity requested are 5 x 384-well plates of tissues with human primary hepatocytes tissues and 10 x 96-well plates of tissues with human primary hepatocyte, liver endothelial cells and kupffer cells

(vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated period of performance is within 60 days after receipt of order (ARO). Perormance shall be FOB Destination and shall be delivered to 9800 Medical Center Drive, Rockville, MD, 20850 between the hours of 8:00 am and 5:00 pm, Eastern Standard Time, Monday through Friday (except on Federal Holidays).

(viii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition.

The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text.

Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions mayinclude blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identif ier and provide theappropriate information with its quotation or offer. Also, the full text of a solicitation provision maybe accessed electronically at these addresses:

https://www.acquisition.gov/browse/index/farhttps://www.hhs.gov/grants/contracts/c ontract-policies-regulations/hhsar/index.html

(End of provision)

The following provisions apply to this acquisition and are incorporated by reference:

•FAR 52.204-7, System for Award Management (Oct 2018) •FAR52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) •FAR 52.212-1, Instructions to Offerors-Commercial Items (Nov2021) •FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov2021) •FAR 52.225-2, Buy American Certif icate (Feb 2021) •HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice(December 18, 2015)

The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and ef fect as if they were given in full text. Upon request, the ContractingOff icer will make their full text available.Also, the full text of a clause maybe accessed electronically atthese addresses:

https://www.acquisition.gov/browse/index/farhttps://www.hhs.gov/grants/contracts/c ontract-policies-regulations/hhsar/index.html

(End of clause)

The following clauses apply to this acquisition and are incorporated by reference:

•FAR 52.204-13, System for Award Management Maintenance (Oct 2018) •FAR 52.204-18, Commercial and GovernmentEntity Code Maintenance (Aug 2020) •FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Nov 2021).Addendum to this FAR clause applies to thisacquisition and isattached.

•HHSAR 352.239-74, Electronic and Information TechnologyAccessibility (December18,2015)

The following provisions and clauses apply to this acquisition and are attached in fulltext.

Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submitcompleted copies as separate documents with theirproposal.

(ix) The provision at FAR clause 52.212-2, Evaluation – Commercial Items, applies to this acquisition.

The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order f rom this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes:

a. Technical capability of the item offered to meet the Government requirement;

b. Price; and

c. Past performance [see FAR 13.106-2(b)(3)].

https://www.acquisition.gov/browse/index/farhttps:/www.hhs.gov/grants/contracts/ https://www.acquisition.gov/browse/index/farhttps:/www.hhs.gov/grants/contracts/

The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s).

A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award.

(x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Items, with its offer.

(xi) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Nov 2021), applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached.

(xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Items, applies to this acquisition. Please see attachment.

(xiii) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices.There are no additional contract requirement(s) or terms and conditions applicable to this acquisition

(xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.

(xv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance;

trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

(xvi) In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identif ication Number (TIN), and the certif ication of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.”

All responses must be received by 3:00PM., Eastern Daylight/Standard Time, on May 15, 2023, and reference Solicitation Number 75N95023Q000181 Questions may be submitted electronically to Chandani Hangilipola, Contract Specialist, at chandani.hangilipola@nih.gov

All quotations must be received by 3:00 PM, Eastern Daylight/ Standard Time, on May 15, 2023.and reference Solicitation Number 75N95023Q00183. Responses must be submitted electronically to Chandani Hangilipola, Contract Specialist at chandani.hangilipola@nih.gov.

Fax responses will not be accepted.

http://www.sam.gov/